Lead optimisation of OXS007417: <i>in vivo</i> PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.

RSC Med Chem · 2024 · PMC11361297 · PMID 39220761

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In contrast, even at 1 mg kg −1 QD, OXS008474 and OXS008255 showed a trend to reduced tumour growth compared to vehicle treated controls.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Lead optimisation of OXS007417: &lt;i&gt;in vivo&lt;/i&gt; PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.

The sentences

Lead optimisation of OXS007417: <i>in vivo</i> PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.